Jacoba van der Zee1, Gerard C van Rhoon. 1. Department of Radiation Oncology, Hyperthermia Unit, Rotterdam, The Netherlands. j.vanderzee@erasmusmc.nl
Abstract
BACKGROUND: For many years, the standard treatment of advanced cervical cancer has been radiotherapy (RT), including brachytherapy. The achievement of locoregional tumour control is essential for cure. Results of RT in early stages are reasonably satisfactory, but locoregional failure rates for stage IIIb and IVa are high. In several randomized trials, the addition of hyperthermia (HT) to RT has been investigated. RANDOMIZED TRIALS: The Dutch Deep Hyperthermia Trial was completed in 1996. In this trial a beneficial effect of additional hyperthermia was clearly demonstrated. Three-year locoregional control and overall survival rates were significantly higher in the RT + HT group than in the RT alone group, while radiation toxicity was not affected. Cost-per-life-year-gained was less than 4,000 Euros. The results of this trial have led to the acceptance of RT plus HT as standard treatment for advanced cervical cancer in the Netherlands. Five trials conducted in Asia have been published, of which three showed significant better complete response, locoregional tumour control and/or disease-free survival rates. One trial showed a trend of better locoregional tumour control and one did not show any benefit. CONCLUSION: Hyperthermia added to standard radiotherapy of locally advanced cervical tumours results in considerable therapeutic gain and is cost-effective. For a beneficial effect, the use of an adequate heating technique is an important requirement.
BACKGROUND: For many years, the standard treatment of advanced cervical cancer has been radiotherapy (RT), including brachytherapy. The achievement of locoregional tumour control is essential for cure. Results of RT in early stages are reasonably satisfactory, but locoregional failure rates for stage IIIb and IVa are high. In several randomized trials, the addition of hyperthermia (HT) to RT has been investigated. RANDOMIZED TRIALS: The Dutch Deep Hyperthermia Trial was completed in 1996. In this trial a beneficial effect of additional hyperthermia was clearly demonstrated. Three-year locoregional control and overall survival rates were significantly higher in the RT + HT group than in the RT alone group, while radiation toxicity was not affected. Cost-per-life-year-gained was less than 4,000 Euros. The results of this trial have led to the acceptance of RT plus HT as standard treatment for advanced cervical cancer in the Netherlands. Five trials conducted in Asia have been published, of which three showed significant better complete response, locoregional tumour control and/or disease-free survival rates. One trial showed a trend of better locoregional tumour control and one did not show any benefit. CONCLUSION:Hyperthermia added to standard radiotherapy of locally advanced cervical tumours results in considerable therapeutic gain and is cost-effective. For a beneficial effect, the use of an adequate heating technique is an important requirement.
Authors: Yu Yuan; Cory Wyatt; Paolo Maccarini; Paul Stauffer; Oana Craciunescu; James Macfall; Mark Dewhirst; Shiva K Das Journal: Phys Med Biol Date: 2012-03-20 Impact factor: 3.609
Authors: Vadim L Stakhursky; Omar Arabe; Kung-Shan Cheng; James Macfall; Paolo Maccarini; Oana Craciunescu; Mark Dewhirst; Paul Stauffer; Shiva K Das Journal: Phys Med Biol Date: 2009-03-13 Impact factor: 3.609
Authors: S Triantopoulou; E Efstathopoulos; K Platoni; N Uzunoglou; N Kelekis; V Kouloulias Journal: Clin Transl Oncol Date: 2012-11-21 Impact factor: 3.405
Authors: Marloes IJff; Bregje van Oorschot; Arlene L Oei; Przemek M Krawczyk; Hans M Rodermond; Lukas J A Stalpers; H Petra Kok; Johannes Crezee; Nicolaas A P Franken Journal: Int J Mol Sci Date: 2018-08-16 Impact factor: 5.923